CorFlow Therapeutics AG ("CorFlow") today announced that Innosuisse, the Swiss Innovation Agency, has awarded the Company a non-dilutive public grant.
TCT18: CorFlow Presents Scientific Findings and is Selected as Finalist in the TCT Shark Tank Innovation Competitionadmin
CorFlow Therapeutics AG today announced that the company has been selected to present the CorFlow Controlled Flow Infusion (CoFI™) technology during the [...]
CorFlow Therapeutics AG today announced that leading interventional cardiologists from Europe, Japan and the United States have joined the CorFlow Scientific Advisory [...]
On March 2nd Medtech Insight, a leading publication covering the global medical device industry, featured CorFlow Therapeutics AG as one of the [...]
CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at the American College of Cardiology (ACC)admin
CorFlow Therapeutics AG today announced that the company will present fundamental new insights into the coronary microcirculation during the annual meeting of [...]
CorFlow Therapeutics AG today announced that Mrs. Esther Gerteis has been appointed CorFlow's VP Medical Affairs and will be a member of [...]
CorFlow Therapeutics AG today announced that the company has completed the CHF 2.6M 1st close of its Seed+ financing round led by [...]
CorFlow Therapeutics AG today announced that its ISO 13485:2016 compliant Quality Management System (QMS) has been certified by the British Standards Institution (BSI).